In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CHPA meeting request

This article was originally published in The Rose Sheet

Executive Summary

Consumer Healthcare Products Association says meeting with FDA is planned in June to discuss the results of a pilot study on 20% benzocaine-containing oral care products. Trade group requested a meeting with the agency in a March 25 letter. Study was conducted after CHPA received a feedback letter from FDA in October 2002, responding to the association's proposed research program on benzocaine for temporary pain relief from toothache. Results address several key questions outlined by FDA, CHPA says, including "assessment of the subject's comprehension of the label directions for dosing, methodology to assess efficacy and the duration of treatment effect." CHPA also plans to discuss proposed protocol to evaluate 10% and 20% benzocaine and proposed OTC label...



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts